Industry Outlook: Healthcare & Life Sciences — Week of March 30, 2026

Market Outlook

• Payers and providers formalize AI-first navigation. UnitedHealthcare’s launch of an AI companion for member navigation, combined with SCAN Group appointing its first chief AI officer, signals that AI-driven engagement and operations are becoming strategic core capabilities, not experiments. For CTOs, this raises competitive expectations around AI-enabled benefits navigation, triage, and care coordination, and will quickly reset patient and clinician experience baselines across markets.
• Clinical intelligence platforms mature in tertiary care. Boston Children’s deployment of a clinical intelligence platform for high-frequency ICU data illustrates that hospitals are moving beyond basic dashboards to real-time, bedside decision support on top of time-series physiologic streams. This is a leading indicator that high-acuity environments will demand scalable data infrastructure, model governance, and robust integration with EHRs and device telemetry over the next 12–24 months.
• Precision medicine and brain-penetrant drugs gain traction. Alumis’ precision immunology strategy in autoimmune disease and Denali’s FDA approval for a brain-penetrant enzyme replacement therapy for Hunter syndrome show regulators and investors backing more targeted, mechanism-based therapeutics. These trends will increase demand for integrated omics, real-world data (RWD) platforms, and companion digital tools to support patient selection, monitoring, and post-marketing evidence generation.

Discussion: CTOs should assume AI-assisted engagement and high-fidelity clinical data platforms will be table stakes and plan architectures that can support patient-specific therapeutics and RWD-heavy evidence strategies.

Headwinds

• VA EHR bribery case heightens procurement scrutiny. The DOJ indictment of the former VA EHR modernization director over contractor gifts around the $16B Cerner project will intensify oversight of large-scale health IT procurements. Expect more rigorous vendor due diligence, conflict-of-interest reviews, and documentation requirements, which can slow decision cycles and demand higher transparency in pricing, performance guarantees, and data governance commitments.
• DOJ antitrust actions target health system market power. The DOJ lawsuit against NewYork-Presbyterian for alleged anticompetitive contracting, alongside broader scrutiny of vertical integration at UnitedHealth, underscores regulators’ focus on health system and payer market power. Large integrated delivery networks and payviders will face tighter guardrails on exclusive arrangements and data use, complicating closed, proprietary data strategies and potentially forcing more open interoperability.
• Geopolitical shocks threaten drug and device supply chains. Coverage of the Iran war’s impact on global shipping, energy prices, and fertilizer markets includes explicit concern about how a Hormuz closure could affect medicines and broader supply chains. For life sciences manufacturers, CDMOs, and large provider systems, this raises the risk of API shortages, logistics delays, and cost spikes that can disrupt clinical trials, pharmacy operations, and device availability.

Discussion: CTOs should anticipate slower, more scrutinized enterprise sales cycles, design architectures that can support multi-party data sharing under antitrust-sensitive conditions, and stress-test supply-dependent digital operations (e.g., pharmacy, inventory, trial logistics).

Tailwinds

• AI adoption expands into coding and revenue cycle. New AI-powered medical coding capabilities from OpenEvidence and a $40M raise for Adonis’ AI platform to boost hospital revenue show rapid uptake of AI in core back-office functions. As margins tighten, hospitals and payers will prioritize AI that improves coding accuracy, reduces denials, and automates documentation, creating strong demand for compliant, explainable models deeply integrated with EHR and billing workflows.
• Real-world data reshapes oncology and rare disease care. New work on how RWD is reshaping the NSCLC patient journey, combined with GeneDx’s progress in genome sequencing for rare disease diagnosis, demonstrates that longitudinal clinical, claims, and genomic data are becoming central to clinical decision-making. This tailwind favors organizations with modern data platforms, strong FHIR/HL7 pipelines, and governance frameworks that can support both care delivery and regulatory-grade evidence.
• Behavioral health and mobile care models gain momentum. Analyses on closing behavioral care gaps, the scaling of direct primary care (DPC), and the growth of mobile clinics indicate sustained demand for distributed, hybrid care models. These approaches require robust telemedicine platforms, remote monitoring, and interoperable records that travel with patients across community settings, creating opportunities for vendors that can provide secure, offline-capable, and standards-based solutions.

Discussion: CTOs can lean into AI for revenue cycle and coding as near-term ROI opportunities while investing in RWD infrastructure and distributed care platforms that align with payer, oncology, and behavioral health strategies.

Tech Implications

• Clinical AI transparency and governance become mandatory. Deloitte’s commentary on AI transparency and the future of computer vision in healthcare, alongside broader debate on AI’s role in Medicare modernization, highlights rising expectations for explainability, auditability, and bias mitigation. Clinical AI will increasingly be evaluated not just on accuracy, but on documentation of training data, model behavior across subpopulations, and alignment with FDA and CMS guidance on software as a medical device and coverage decisions.
• Data integration and FHIR-first architectures move center stage. Multiple pieces emphasize the need to ‘unleash data’s power through integration’ and Boston Children’s work shows the operational reality of ingesting high-frequency device data, EHR data, and analytics into a single clinical intelligence layer. This reinforces the case for FHIR-native data stores, event-driven architectures, and standardized terminologies (SNOMED, LOINC, RxNorm) to support both operational use cases and AI/ML pipelines without bespoke integrations for every system.
• Clinician-in-the-loop development emerges as retention strategy. Evidence that involving clinicians in technology development improves retention reframes co-design as not only a usability best practice but a workforce stabilization lever, especially as younger nurses become a growing share of the workforce. For engineering teams, this means formalizing clinician-in-the-loop design, feedback, and validation processes, and instrumenting products to measure impact on workload, burnout, and satisfaction.

Discussion: Engineering leaders should prioritize AI governance frameworks, FHIR-centric integration patterns, and structured clinician co-design processes as first-class elements of their product and platform roadmaps.

CTO Action Items

This week, prioritize building or strengthening an enterprise AI governance framework that covers transparency, documentation, and monitoring for both clinical and back-office AI, anticipating payer and regulator expectations. Accelerate your move toward a FHIR-first, event-driven data architecture that can support high-frequency clinical data, RWD use cases, and integration with revenue cycle AI tools. Given intensifying antitrust and procurement scrutiny, review your data-sharing, contracting, and interoperability strategies to ensure they can withstand regulatory review while still enabling competitive differentiation. Finally, formalize clinician-in-the-loop design programs—especially with early-career nurses and specialists—to ensure new digital tools improve retention and care quality rather than adding friction.